In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoCor completes trial enrolment:

This article was originally published in Clinica

Executive Summary

CryoCor has completed enrolment of more than 170 patients in a 12-month pivotal clinical study to assess the use of its cryoablation technology in atrial fibrillation. The device, also named CryoCor, was recently approved in the US for the treatment of right atrial flutter (see Clinica No 1268, p 2). The San Diego, California-based company said that it expected to file a PMA for the treatment of atrial fibrillation in late 2008, with approval anticipated in 2009.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049575

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel